Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease

T cells from patients with Parkinson’s disease recognize α-synuclein peptides

(2017) David Sulzer et al.   NATURE

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

(2016) Bruno Dubois et al.   Alzheimers & Dementia

Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes

(2015) Lauren Walker et al.   ACTA NEUROPATHOLOGICA

Clinical Features of Alzheimer Disease With and Without Lewy Bodies

(2015) Eun Joo Chung et al.   JAMA Neurology

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference

(2015) Ryotaro Ishii et al.   PLoS One

Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms

(2014) Sarosh R. Irani et al.   ANNALS OF NEUROLOGY

Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models

(2014) D. Games et al.   JOURNAL OF NEUROSCIENCE

Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases

(2014) Jing L Guo et al.   NATURE MEDICINE

Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite–like aggregates

(2014) Laura A Volpicelli-Daley et al.   Nature Protocols

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease

(2014) John M. Woulfe et al.   PARKINSONISM & RELATED DISORDERS

Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinson’s Disease Patients and Controls

(2014) Walter Maetzler et al.   PLoS One

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration

(2014) Hien T. Tran et al.   Cell Reports

A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank

(2013) Jon B. Toledo et al.   Alzheimers & Dementia

Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease

(2013) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale

(2013) Glenn T. Stebbins et al.   MOVEMENT DISORDERS

Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study

(2013) Yaroslau Compta et al.   PARKINSONISM & RELATED DISORDERS

Neuropathologic substrates of Parkinson disease dementia

(2012) David J. Irwin et al.   ANNALS OF NEUROLOGY

New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications

(2012) Rizwan S Akhtar et al.   Expert Review of Neurotherapeutics

The significance of defining preclinical or prodromal Parkinson's disease

(2012) C. Warren Olanow et al.   MOVEMENT DISORDERS

Naturally occurring  -synuclein autoantibody levels are lower in patients with Parkinson disease

(2012) D. Besong-Agbo et al.   NEUROLOGY

The robust electrochemical detection of a Parkinson's disease marker in whole blood sera

(2012) Thomas Bryan et al.   Chemical Science

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

(2011) Leslie M. Shaw et al.   ACTA NEUROPATHOLOGICA

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

(2011) Marina A. Gruden et al.   JOURNAL OF NEUROIMMUNOLOGY

Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease

(2011) Kathleen M. Shannon et al.   MOVEMENT DISORDERS

α-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson's Disease Patients

(2011) Kiran Yanamandra et al.   PLoS One

Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders

(2010) Thomas G. Beach et al.   ACTA NEUROPATHOLOGICA

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

(2010) John Q. Trojanowski et al.   Alzheimers & Dementia

When does Parkinson's disease begin?

(2010) Carles Gaig et al.   MOVEMENT DISORDERS

Incidental Lewy body disease: Clinical comparison to a control cohort

(2010) Charles H. Adler et al.   MOVEMENT DISORDERS

Systematic review of levodopa dose equivalency reporting in Parkinson's disease

(2010) Claire L. Tomlinson et al.   MOVEMENT DISORDERS

CSF amyloid   1-42 predicts cognitive decline in Parkinson disease

(2010) A. Siderowf et al.   NEUROLOGY

Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms

(2010) Thibaud Lebouvier et al.   PLoS One

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Lewy Body Pathology in Normal Elderly Subjects

(2009) William R. Markesbery et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

(2008) Thomas G. Beach et al.   ACTA NEUROPATHOLOGICA